NewAmsterdam Pharma Co N.V Book Value Per Share Growth & History (NAMS)
NewAmsterdam Pharma Co N.V's book value per share was $5.97 for fiscal 2025.
View full NewAmsterdam Pharma Co N.V company overviewNewAmsterdam Pharma Co N.V annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.97 | -$1.04 | −14.77% |
| 2024 | 2024-12-31 | $7.01 | $3.51 | +100.45% |
| 2023 | 2023-12-31 | $3.50 | -$1.78 | −33.68% |
| 2022 | 2022-12-31 | $5.27 | $15.32 | — |
| 2021 | 2021-12-31 | -$10.05 | $4.56 | — |
| 2020 | 2020-12-31 | -$14.61 | — | — |
NewAmsterdam Pharma Co N.V quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.37 | -$1.55 | −22.44% |
| Q1 2026 | 2026-03-31 | $5.70 | -$1.23 | −17.71% |
| Q4 2025 | 2025-12-31 | $5.97 | -$1.04 | −14.77% |
| Q3 2025 | 2025-09-30 | $6.43 | $2.32 | +56.50% |
| Q2 2025 | 2025-06-30 | $6.92 | $2.62 | +60.76% |
| Q1 2025 | 2025-03-31 | $6.93 | $2.34 | +50.99% |
| Q4 2024 | 2024-12-31 | $7.01 | $3.51 | +100.45% |
| Q3 2024 | 2024-09-30 | $4.11 | — | — |
| Q2 2024 | 2024-06-30 | $4.30 | -$0.25 | −5.39% |
| Q1 2024 | 2024-03-31 | $4.59 | — | — |
| Q4 2023 | 2023-12-31 | $3.50 | -$1.78 | −33.68% |
| Q2 2023 | 2023-06-30 | $4.55 | — | — |
| Q4 2022 | 2022-12-31 | $5.27 | — | — |
NewAmsterdam Pharma Co N.V book value per share trends
Over the last five fiscal years, NewAmsterdam Pharma Co N.V's book value per share increased from -$14.61 to $5.97, a change of $20.58. The latest reported quarter, Q2 2026, shows $5.37.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NewAmsterdam Pharma Co N.V source filings ↗